[
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)",
    "summary": "RAHWAY, N.J., February 28, 2026--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC",
    "url": "https://finnhub.io/api/news?id=b51f0c7672756c9dcaa22145cad3be9bf9627e6db96db2df5a24a8ff172a9ecc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772291100,
      "headline": "KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)",
      "id": 139264479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., February 28, 2026--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC",
      "url": "https://finnhub.io/api/news?id=b51f0c7672756c9dcaa22145cad3be9bf9627e6db96db2df5a24a8ff172a9ecc"
    }
  },
  {
    "ts": null,
    "headline": "WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)",
    "summary": "RAHWAY, N.J. & NUTLEY, N.J., February 28, 2026--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients",
    "url": "https://finnhub.io/api/news?id=5753695d32f676cdaaae934860d8b8a562a1270ed18994735c9d04a9ee8b4c9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772290800,
      "headline": "WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)",
      "id": 139264480,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & NUTLEY, N.J., February 28, 2026--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients",
      "url": "https://finnhub.io/api/news?id=5753695d32f676cdaaae934860d8b8a562a1270ed18994735c9d04a9ee8b4c9a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Reshapes Drug Business As Keytruda Era Nears Turning Point",
    "summary": "Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious Diseases, with new executive leadership. The move is described as a response to the upcoming patent expiration for Keytruda, the company’s flagship cancer therapy. Alongside the reorganization, Merck released new late stage clinical data on Keytruda combinations in cancer and on HIV and RSV treatment candidates. For you as an investor, this is a meaningful shift for a...",
    "url": "https://finnhub.io/api/news?id=75a59370bb70ab315be7b735acfd18786f4e3ccbc950007d912cb4821586624c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772252907,
      "headline": "Merck Reshapes Drug Business As Keytruda Era Nears Turning Point",
      "id": 139260237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious Diseases, with new executive leadership. The move is described as a response to the upcoming patent expiration for Keytruda, the company’s flagship cancer therapy. Alongside the reorganization, Merck released new late stage clinical data on Keytruda combinations in cancer and on HIV and RSV treatment candidates. For you as an investor, this is a meaningful shift for a...",
      "url": "https://finnhub.io/api/news?id=75a59370bb70ab315be7b735acfd18786f4e3ccbc950007d912cb4821586624c"
    }
  }
]